SCHEMBL71414

SCHEMBL71414

CC(C)c1ccc2c(c1)OCCO2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.62
PTGS2 P35354 1/20 0.62
AOC3 Q16853 1/20 0.53
HTT P42858 3/20 0.49
TRPV1 Q8NER1 1/20 0.48
KDM1A O60341 3/20 0.48
MAOA P21397 2/20 0.48
MAOB P27338 2/20 0.48
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
SLC6A2 P23975 2/20 0.44
SLC6A4 P31645 2/20 0.44
SLC6A3 Q01959 2/20 0.44
KCNH2 Q12809 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
LMNA P02545 2/20 0.44
MAPT P10636 2/20 0.44
TP53 P04637 1/20 0.44
BLM P54132 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15982277 0.94 PTGS1 (0.57) PTGS1PTGS2AOC3HTTTRPV1
SCHEMBL11928867 0.94 PTGS1 (0.57) PTGS1PTGS2AOC3HTTTRPV1
SCHEMBL9908308 0.94 PTGS1 (0.57) PTGS1PTGS2AOC3HTTTRPV1
SCHEMBL15982321 0.94 PTGS1 (0.57) PTGS1PTGS2AOC3HTTTRPV1
SCHEMBL15982273 0.94 PTGS1 (0.57) PTGS1PTGS2AOC3HTTTRPV1
SCHEMBL20091607 0.94 PTGS1 (0.57) PTGS1PTGS2AOC3HTTTRPV1
SCHEMBL16541175 0.92 PTGS1 (0.54) PTGS1PTGS2AOC3HTTTRPV1
SCHEMBL2607487 0.92 PTGS1 (0.54) PTGS1PTGS2AOC3HTTTRPV1
SCHEMBL70200 0.87 MEN1 (0.55) PTGS1PTGS2HTTCYP3A4CYP2D6
SCHEMBL25066870 0.83 PTGS1 (0.59) PTGS1PTGS2AOC3HTTKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239804-A1 FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 BAYER AKTIENGESELLSCHAFT (DE) 2024-07-18 US disclosed
US-20240228491-A1 METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 US disclosed
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2024-07-04 US disclosed
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2024-07-04 US disclosed
US-20240209017-A1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-27 US disclosed
US-20240209017-A1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-27 US disclosed
WO-2024059107-A1 IKZF2 AND CK1-ALPHA DEGRADING COMPOUNDS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-03-21 WO disclosed
US-20240067638-A1 IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS BRISTOL MYERS SQUIBB CO (US) 2024-02-29 US disclosed
US-20240067638-A1 IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS BRISTOL MYERS SQUIBB CO (US) 2024-02-29 US disclosed
US-11912714-B2 Spiropyrrolidine derived antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2024-02-27 US disclosed
US-7179826-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-02-20 US disclosed
US-7169800-B2 Imidazole compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-01-30 US disclosed
US-20070010503-A1 Compounds useful for treating neurodegenerative disorders LIGHTHOUSE CAPITAL PARTNERS VI, L.P. 2007-01-11 US disclosed
US-20070010503-A1 Compounds useful for treating neurodegenerative disorders LIGHTHOUSE CAPITAL PARTNERS VI, L.P. 2007-01-11 US disclosed
US-20070004762-A9 Pyrrolopyrimidines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2007-01-04 US disclosed
US-7157476-B2 Aminofurazan compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-01-02 US disclosed
US-7157476-B2 Aminofurazan compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-01-02 US disclosed
WO-2004103998-A1 QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-02 WO disclosed
US-20030050299-A1 An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents GENZYME CORPORATION 2003-03-13 US disclosed
US-20030050299-A1 An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents GENZYME CORPORATION 2003-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010503-A1 Compounds useful for treating neurodegenerative disorders CLN6, NLN, ACHE PTGS1 1107/4885PTGS2 1005/4885AOC3 449/4885
US-20070004762-A9 Pyrrolopyrimidines useful as inhibitors of protein kinase PRKDC, MAP3K20, MAP3K5 PTGS1 1364/4885PTGS2 1329/4885AOC3 4669/4885
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK2, ROCK1, RHOA PTGS1 361/4885PTGS2 349/4885AOC3 4186/4885
US-20240209017-A1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING STING1, CGAS, MAVS PTGS1 712/4885PTGS2 998/4885AOC3 4477/4885
US-11912714-B2 Spiropyrrolidine derived antiviral agents ACE, ACE2, PKD1 PTGS1 516/4885PTGS2 2132/4885AOC3 4484/4885
US-20240228491-A1 METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF MAT1A, AMD1, MAT2B PTGS1 1127/4885PTGS2 1847/4885AOC3 2389/4885
US-20240067638-A1 IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS TLR9, TLR1, TLR7 PTGS1 384/4885PTGS2 1452/4885AOC3 3540/4885
US-20240239804-A1 FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 GPR84, GPR88, FFAR1 PTGS1 608/4885PTGS2 966/4885AOC3 4085/4885
US-20030050299-A1 An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents UGCG, UGGT1, LCLAT1 PTGS1 1579/4885PTGS2 1948/4885AOC3 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.